RET mutation

YUP!She updated me on a new trial for my RET mutation just before my pancreatic cancer returned. Stage 4 in liver/lungs.Been following me with regular liquid biopsies & tumor markers.Started the trial.Meds killed the cancer in 30 days!! PM me. (@randyeringler)

Breaking down the hidden CODE ! Biomarker analysis of CodeBreak 100 ⬇️ KRAS G12C mut NSCLC 🎯Sotarasib >12 mo PFS benefit in only 23% Who benefits ? ➡️Wild type KEAP1 (STK11 mut/wt) ➡️PI3K, PDGFR, RET mutations ➡️Lower baseline ctDNA ➡️ @JCO_ASCO @oncologician @OncBrothers (@shikharkumar89)

Interesting preclinical study shows MDM2 amplificn occurs in lung adenoca w oncogenic driver mutations (METex14 36%, EGFR 8%, RET 12%, ALK 10%) MDM2 inhibitors + MEKi may be effective here ⁦@charlesrudin⁩ ⁦@JTOonline⁩ ⁦@OncoAlert⁩ #LCSM https://t.co/exkb0goXKE (@DrJNaidoo)

📳 Osimertinib and Selpercatinib in patients with RET mutation as resistance mechanism in EGFR+ve mNSCLC 🔹 ORR 50% 🔹 DCR 83% 🔹 Median DOT 7.9mo @SuyogCancer @OncoAlert @LungSummit @StephenVLiu @ArndtVogel @oncologician @SewantiLimaye #medtwitter #precisiononcology (@saadvikdr)

Join us on 4/26 for a Lung Cancer Webinar with @HatimHusainMD @UCSDCancer #DrMassarelli @COHMedOnc @MNagasaka @UCIrvineHealth on the Treatment of other Targetable Mutations (MET/RET). Sponsored by @AstraZenecaUS Register at https://t.co/gpcEnZ4HlY (@MOASC_Office)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers https://t.co/XkfJOctwuM (@AndresFCardonaZ)

For patients with EGFR-mutant NSCLC with an acquired RET fusion as a mechanism of EGFR inhibitor resistance, the addition of selpercatinib to osimertinib was feasible, safe, and offered clinical benefit, supporting the prospective evaluation of this combination. (@RETpositive)

Happy to contribute, finally out: Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers https://t.co/PoPkMVi39V #LCSM @EGFRResisters (@trnsltnl)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

-Led and/or oversaw notable approvals in lung cancer including targeted therapies for MET exon 14 skipping mutations and RET fusions -Dedicated advocate who engages with the greater scientific community to increase the evidence base for treating older adults with cancer. (@YLeyfman)

Like we remember imp bus numbers, remember 2 most imp codons of #RET gene mutation Codon 918 cause most aggressive #MedullaryThyroidCancer & characteristic #MEN2B phenotype Codon 634 cause aggressive MTC & #MEN2A syndrome For other codons check their cancer risk before you act (@RajivSarin5)

Question to experts on RET alteration @VivekSubbiah @jacobadashek @Dr_R_Kurzrock -Do RET point mutations, play a role in lung cancer oncogenesis & can they be targeted? What is the probability of not detecting RET fusion in DNA-RNA sequencing?Best diagnostic test for RET fusions? (@UmutDisel)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @andreevdrakhlin https://t.co/2m3BXONoLn (@VivekSubbiah)

Men 2b (RET mutation) 3M Marfanoid(like marfan but without aorta or eye involvement) Mtc Mucosal neuromas(tongue, git) 1P Pheochromacytoma (@shettyswaaaa13)

Congrats to you & the study team! Not too long ago who will believe that NSCLC will respond to immunotherapy. Now it’s the era of small molecules. There’s only a few thousands RET mutated NSCLC diagnosed each year in US. Just the speed of study completion is a major achievement!! (@HenrychihangFu1)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @JCOPO_ASCO @andreevdrakhlin @OncoAlert https://t.co/khTk21IHMq (@VivekSubbiah)

Targeting RET-mutated thyroid and lung cancer in the personalised medicine era https://t.co/8TcaHxTLNL (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @JCOPO_ASCO @OncoAlert https://t.co/bOKRhstki1 (@VivekSubbiah)

⭐️Systemic & CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases 🎯🧬#PrecisionMedicine @JCOPO_ASCO @andreevdrakhlin @OncoAlert https://t.co/lTc9gigW9u (@VivekSubbiah)

Excellent sessions at #WCTC2022 on #thyroidcancer clinical management with a special 🎯 focus on #RET mutations and #RETinhibitors Thanks to @ThyroidCongress @gthyroid57 @Jasosamd @pinobarbe Mike Tuttle @MSKCC_OncoNotes Lori Wirth (@AndreaCorsello)

@MarkZafereoMD at #HNCS22 highlights anaplastic thyroid cancer is likely more than 1 disease with mutually exclusive BRAF and RET mutations. Promising combinations of BRAF and immunotherapy! trial coming to Cleveland Clinic @JLGeigerMD @YilmazMDPhD (@NeilWoodyMD)

Over 40% of patients with RET-mutant MTC who received selpercatinib, a highly selective RET inhibitor, reported clinical meaningful improvements in diarrhea in a phase I/II study. (@VivekSubbiah)

💫Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial @OncJournal @OncoAlert #thycsm https://t.co/uvDzeEb8l2 (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @JCOPO_ASCO @andreevdrakhlin https://t.co/ZKtdfQ3l8x (@VivekSubbiah)

🧬 #RET #precisionmedicine RET mutations👉 Germline events in hereditary MEN syndrome & somatic RET mutations sporadic MTC. RET fusions 👉 NSCLC 🫁, papillary thyroid cancer, many other cancers 🎯 @MCT_AACR @OncoAlert https://t.co/6WaGXXBTOj (@VivekSubbiah)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib in RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases @RETpositive @ASCO_pubs @OncoAlert https://t.co/qT7qVo27Gb (@VivekSubbiah)

⭐️FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions 🎯🧬💊 @CCR_AACR @harpreet_md @OncoAlert https://t.co/oYudrRhCdd (@VivekSubbiah)

⭐️FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions 🎯💊🧬 @CCR_AACR @harpreet_md @OncoAlert @RETpositive @RetRenegades https://t.co/6jjvAC3MIC (@VivekSubbiah)

The availability of targeted agents for pts w/ advanced NSCLC who harbor mutations in EGFR, RET, MET, & KRAS has led to improved outcomes & provided greater flexibility for treatment-naïve and pretreated populations @Pradnya_PatilMD @ClevelandClinic #lcsm https://t.co/jcG0sEnUIu (@OncLive)

⭐️RET gene alterations: RET mutations are seen as germline events in hereditary MEN syndrome and somatic RET mutations are seen in sporadic MTC. RET fusions are seen in NSCLC, papillary thyroid cancer, and many other cancers @MCT_AACR @RETpositive https://t.co/6WaGXXBTOj (@VivekSubbiah)

Now I have to derail: #GITwitter #ColonCancerPrevention #OncoTwitter “Mutations of RET are associated to a subset of colorectal cancer” https://t.co/765V9oaO4i (@ShimaghavimiMD)

Over 40% of patients with RET-mutant Thyroidcancer on selpercatinib, reported clinical meaningful improvements in diarrhea Patient‐Reported Outcomes with Selpercatinib & RET‐Mutant Medullary Thyroid Cancer @OncJournal #TumorBoardTuesday https://t.co/NFHfuhfeIB (@VivekSubbiah)

In addition, they have shown activity against somatic (60%–90%) or germline (100%) RET mutations seen in medullary thyroid cancer (@VivekSubbiah)

RET fusions are seen in NSCLC (2%) and papillary thyroid cancers (PTC; 10%–20%), whereas somatic (60%–90%) or germline (100%) RET mutations are seen in medullary thyroid cancer (@VivekSubbiah)

Now Vivek level question- why do you not see oncogenic RET mutations (only fusions) in NSCLC while you do in medullary thyroid? (Of course i did not know until i learned from no other than Lori Wirth) (@DrSteveMartin)

Over 40% of patients with RET-mutant MTC who received selpercatinib, a highly selective RET inhibitor, reported clinical meaningful improvements in diarrhea in a phase I/2 study. (@VivekSubbiah)

Advances in the Management of Thoracic Malignancies #ِAMTM Treatment of Stage IV NSCLC with other mutations (Met/Ret) Speaker: Dr. Christian Rolfo @ChristianRolfo The session is full but you can see the live broadcast here https://t.co/Zydpt2Zp4q (@Oncology_Events)

⭐️RET fusions➡️2% -lung cancer, ~20% papillary thyroid cancer, <1% multiple cancers. ⭐️RET mutations➡️Medullary thyroid cancer 60 % sporadic,100%hereditary #Selpercatinib & #Pralsetinib Selective RET inhibitors @trendscancer @CellPressNews https://t.co/cxDhYhMVce (@VivekSubbiah)

🔺RET fusions👉 2% -lung cancer, ~20% papillary thyroid cancer, <1% multiple cancers. 🔺RET mutations👉Medullary thyroid cancer 60 % sporadic,100%hereditary 🔺#Selpercatinib & #Pralsetinib 👉selective RET inhibitors @trendscancer 🔺Questions for future https://t.co/cxDhYhMVce (@VivekSubbiah)